Medivation Inc., the start-up that persuaded Pfizer Inc., the worlds biggest drugmaker, to help develop Dimebon, may be ready to release new research data during the first week of March, said Bengt Winblad, head of Alzheimers research at the Karolinska Institute in Stockholm and a leader of the European trials for the product. The study may confirm a 2008 finding in Russia that patients functioned better and thought more clearly after swallowing Dimebon tablets three times a day.
The data augur a make-or-break moment for San Francisco- - - - - >

It was January 2004, and the attorneys were negotiating in a conference room on the ninth floor of the federal courthouse in Boston, where Loucks was head of the health-care fraud unit of the U.S. Attorneys Office. One of Pfizers units had been pushing doctors to prescribe an epilepsy drug called Neurontin for uses the Food and Drug Administration had never approved.
In the agreement the lawyers eventually hammered out, the Pfizer unit, Warner-Lambert, pleaded guilty to two felony counts of marketing a drug for unapproved uses. - - - - >

“The Middle East is becoming one of our key emerging markets,” Jean-Michel Halfon, head of Pfizers emerging markets unit, said in an interview in Dubai. “This is a market where we should see double-digit growth and where Pfizer should be able to exceed $1 billion in sales.”
Pfizer plans to add at least $3 billion in annual revenue from sales in developing countries by 2012. It is among major pharmaceutical companies seeking increased sales in emerging countries such as China as revenue in mature markets in the - - - - >

Still, both companies saw their profits dip in the quarter, Pfizer because heavy cost-cutting wasnt enough to offset an 8 percent drop in revenue and a higher tax rate, Bristol-Myers because of higher taxes on top of a sizable litigation charge.
The stronger dollar reduced the value of sales in the quarter for most U.S. drugmakers, so Pfizer, Bristol-Myers Squibb and most other large pharmaceutical companies didnt meet analysts revenue expectations.
But unlike the many other drugmakers who have complained that the global recession added to the problem by reducing spending by consumers, particularly Americans who have lost health insurance with their - - - - >

Glaxos sales and research experience will be combined with Pfizers pipeline to give the new company control of almost 20 percent of the market for treating the deadly virus. The new company will have 11 drugs and 6 experimental compounds, the companies said today in a statement.
London-based Glaxo, which sells Combivir and Epzicom for HIV, made history in 1987 when its predecessor company, Burroughs Wellcome, developed a drug that stopped the virus from replicating in cells. The British drugmaker has since lost ground to Gilead after - - - - >

Talks between Poussot, 57, and Pfizer CEO Jeffrey Kindler, 53, broke down in October when Kindler told Poussot he didnt think he could obtain financing because of the meltdown in the banking industry, according to a U.S. regulatory filing. The acquisition almost fell apart again in December, when an unnamed rival drugmaker considered making a bid.
Wyeth, based in Madison, New Jersey, agreed on Jan. 26 to sell itself to New York-based Pfizer in a transaction valued at about $64 billion. Pfizer, the worlds biggest drugmaker, gains - - - - >